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he Changing Face
f Cardiovascular Risk*
cott M. Grundy, MD, PHD
allas, Texas
rad et al. (1,2) have published two reports in this issue
f the Journal that examine several issues related to coronary
rtery calcium (CAC) as a measure of coronary atheroscle-
osis and as a predictor of atherosclerotic cardiovascular
isease (ASCVD) events. One report (1) indicates that
AC scores predict ASCVD events independent of stan-
ard risk factors and C-reactive protein (CRP). The second
2) reports that treatment of patients with a cocktail of
lpha-tocopherol, vitamin C, and atorvastatin does not
odify the progression of CAC over time. The latter study
ncluded a small trial of clinical end points. In this trial,
he combination of therapies did not significantly reduce
SCVD events, although the small sample size and rela-
ively low event rates appeared insufficient to provide a
efinite outcome.
See pages 158 and 166
To appreciate the significance of these reports it is
ecessary to examine the numbers in some detail. A striking
eature of both studies was the unexpectedly low rates of
ajor coronary events in persons who otherwise were
rojected to be at a relatively high risk. The first study (1)
easured CAC in 4,903 healthy subjects and then followed
hem for an average of 4.3 years for a combined outcome of
oronary event rates (including non-fatal myocardial infarc-
ion [MI], coronary bypass surgery, percutaneous coronary
ngioplasty, and coronary death), non-hemorrhagic stroke,
nd peripheral vascular surgery. Among all 4,903 subjects,
19 experienced ASCVD events; of the latter, only 34%
ere listed as “hard” coronary heart disease (CHD) (myo-
ardial infarction  coronary death). In addition, only 40%
f total CHD events were hard CHD events. Out of all
ubjects, 686 had CAC scores of 110 to 399 Agatston units;
hese scores signify at least moderate coronary atheroscle-
osis. In these subjects, event rates for total CHD events
ere only 1.3% per year, and for hard CHD events, only
.58% per year. Another 450 subjects had CAC scores
400, which should indicate advanced coronary atheroscle-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Center for Human Nutrition, Departments of Clinical Nutrition and
nternal Medicine, and Veterans Affairs Medical Center, University of Texas
outhwestern Medical Center at Dallas, Dallas, Texas. One of the studies used theo
rug atorvastatin, which is made by Pfizer. The author has received honoraria
upported by Pfizer.osis; in these patients, event rates were 3.26% and 1.1% per
ear for total CHD and hard CHD, respectively. At the
eginning of the study, subjects underwent Framingham
isk scoring to determine 10-year risk for hard CHD events
s described in the National Cholesterol Education Pro-
ram’s Adult Treatment Panel III (NCEP ATP III) report
3). Among all subjects, 654 had a projected 10-year risk for
ard CHD of 10% (or 1% per year); 506 scored a
0-year risk of 10% to 20% (1% to 2% per year); and 86
rojected a 20% 10-year risk (2% per year). In the
ntermediate-risk group (i.e., those projected to have 1% to
% of hard events per year) hard CHD events were in fact
nly about 0.4% per year. Likewise those predicted to have
2% per year risk for hard CHD showed an actual rate of
nly 0.9% per year. In both intermediate- and high-risk
roups, only those with the highest CAC scores (upper
ertile for projected risk ranges) had actual rates of hard
HD approaching the projected level of risk. Thus, CAC
easurement clearly added information to the Framingham
rojection; furthermore, only in those in the highest tertile
f CAC scoring for a given Framingham category did
ramingham scoring accord with the observed rate.
In the second study (2), 1,005 healthy subjects with CAC
cores above the 80th percentile for age and gender were
andomized to the combination of atorvastatin, vitamin C,
nd vitamin E versus placebo. After 4.3 years, the thera-
eutic arm showed a non-significant trend toward a reduc-
ion of ASCVD events; moreover, progression of CAC was
naltered by drug therapy. The lack of a significant reduc-
ion of ASCVD events with therapy that included atorva-
tatin likely was due in part to the small size of the trial. But
lso important was the low baseline rate of CHD events in
group that otherwise was projected to be at a relatively
igh risk. For example, in the placebo group, rates for total
HD events and hard CHD events were only 2.03% and
.77% per year, respectively.
The findings of this trial suggest that absolute rates of
ard CHD events are only about half of those projected
rom Framingham risk scoring (3). In other recent clinical
rials (4,5), hard CHD events were lower than might have
een expected. Until recently, the primary end point of most
holesterol-lowering trials has been MI  coronary death
hard CHD) (6–8). Unexpectedly low rates of hard CHD
vents even in so-called high-risk groups raise the question
f whether hard CHD is still a meaningful end point for
linical trials. Low rates of ASCVD deaths especially make
otal mortality a problematic end point. The findings of
ower rates of hard CHD in clinical trials than those
redicted by older prospective studies may have several
auses: healthy volunteer effect, prevention of acute MI
hrough angioplasty or thrombolysis in patients with acute
oronary syndromes, institution of preventive therapies in
he early stages of coronary disease, improved treatment of
stablished ASCVD to prevent death, and widespread use
f preventive measures in the general population (e.g., less
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ontrol).
The question therefore must be asked whether projec-
ions of total ASCVD events are now preferred over hard
HD as an end point in prevention trials as well as in risk
rediction in clinical practice. There is a growing recogni-
ion that non-fatal ASCVD events are costly in many
ays—financial, social, and personal. In the case of risk
rediction, it may be useful to retain the current categories
f risk but to change the end points that define these categories
o be more inclusive of all ASCVD events (Table 1).
ecause any ASCVD event will be costly, it is likely that
ost-effectiveness of preventive therapies will not be sub-
tantially eroded by focusing on all ASCVD events instead
f hard CHD events. A disadvantage for clinical trial
utcomes of course is that practice standards may vary and
hus total ASCVD events will be “softer” than for hard
HD. Nonetheless, the changing presentation of ASCVD
vents requires a more inclusive outcome to define end
oints. It seems particularly important to include stroke
mong outcomes because of recent evidence that preventive
easures affect stroke outcomes similarly to coronary out-
omes.
Finally, the question can be raised about whether CAC
easurement has a role in risk assessment of patients
ithout established ASCVD or diabetes. Framingham risk
coring can still be used as the first step to screen persons for
otential risk. As shown in one of the studies (1), in persons
ound to have a risk of 10% per 10 years, whether hard
HD or total ASCVD is used as the end point, absolute
0-year risk is too low to warrant CAC measurement. For
hose who have a 20% risk per 10 years, CAC measurement
ikewise adds little predictive information of value. On the
ther hand, in the Framingham risk range of 10% to 20%
er 10 year, CAC measurements carry the greatest infor-
ation. Persons who have a CAC score of 100 Agatston
nits (approximately the upper tertile for this category) can
e elevated to a high-risk level. If this approach is taken, the
egative predictive power of lower CAC scores must also be
sed in this intermediate-risk category; thus, a low CAC
core should move a person to the lower-risk zone because
f the paucity of events in those with lower scores. Presum-
able 1. Suggested Changes in Cardiovascular End Points to
efine Projected Risk Categories
10-Year Risk for Event
Absolute Risk
Category
Hard CHD*
(Framingham [3])
Total ASCVD†
(Proposed)
ower to moderate 10% 10%
oderately high
(intermediate)
10–20% 10–20%
igh 20% 20%
Hard CHD: acute mycocardial infarction  coronary death; †total ASCVD:
oronary heart disease events (acute coronary syndromes, coronary artery procedures,
nd coronary death)  strokes (fatal and non-fatal).
ASCVD  atherosclerotic cardiovascular disease; CHD  coronary heart disease.bly there is some CAC range (e.g., 50 to 100 Agatston
4nits) that should keep a person in the intermediate-risk
ange; unfortunately, the study by Arad et al. (1) did not
ave the power to definitively identify this middle group. A
arger study in the projected intermediate-risk range (10-
ear risk of 10% to 20%) is needed to more accurately
e-assign individuals to risk category using CAC measure-
ent. Moreover, the potential for other risk makers, such as
RP, to adjust risk in this category deserves additional
tudy as well. The treatment arm of this study suggests that
AC measurement is of little utility in monitoring progres-
ion of atherosclerosis.
In summary, the studies by Arad et al. (1,2) provide useful
nformation in two areas. First, they strongly suggest that
or a variety of reasons, coronary atherosclerosis is changing
n its clinical manifestations. There appear to be fewer
on-fatal MIs and coronary deaths than in the past, at least
ccording to projections from Framingham scoring (3). It is
ikely that many persons with early coronary disease or those
dmitted to the hospital for acute coronary syndromes are
ot progressing to myocardial infarction because of earlier
nd more intensive intervention; in addition, improved
anagement of established CHD results in fewer deaths.
ther forms of ASCVD now predominate and probably
epresent the preferred end point for clinical trials. For this
eason, it is suggested that clinical trialists in the cardiovas-
ular field develop a common ASCVD end point through
onsensus; if this were to be done, it would be possible to
ore reliably compare the results of different clinical trials.
urthermore, CAC measurements appear to have clinical
tility only in persons with intermediate risk in whom
esting can more accurately triage individuals into lower-,
ntermediate-, and higher-risk categories for ASCVD
vents so that appropriate preventive strategies can be
nstituted.
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